Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

Trial Details

NCT ID
NCT04851119
Phase
PHASE1 / PHASE2
Sponsor
Children's Oncology Group
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orange, California, United States|33.78779,-117.85311
  • Palo Alto, California, United States|37.44188,-122.14302
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • PART A: Patients must be \>= 12 months and =\< 21 years of age at the time of study enrollment
  • PART B: Patients must be \>= 12 months and =\< 30 years of age at the time of study enrollment
  • Patients with recurrent or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors are eligible. Patients must have had histologi…
  • PART A: Patients with relapsed or refractory solid tumors, including patients with non-Hodgkin lymphoma and desmoid tumors

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →